The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 17, 2016

Filed:

Feb. 27, 2013
Applicant:

Merck, Sharp & Dohme Corp.;

Inventors:

Mihir Mandal, Westfield, NJ (US);

Timothy A. Blizzard, Princeton, NJ (US);

Helen Chen, Marlboro, NJ (US);

Harry Chobanian, Aberdeen, NJ (US);

Yan Guo, Westfield, NJ (US);

Barbara Pio, West Orange, NJ (US);

Zhicai Wu, Montvale, NJ (US);

Tesfaye Biftu, Freehold, NJ (US);

William J. Greenlee, Teaneck, NJ (US);

Johnny Zhaoning Zhu, Slough, GB;

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/44 (2006.01); C07D 401/06 (2006.01); C07D 417/14 (2006.01); C07D 405/06 (2006.01); A61K 45/06 (2006.01); A61K 31/365 (2006.01); A61K 31/4365 (2006.01); A61K 31/443 (2006.01); A61K 31/4439 (2006.01); A61K 31/616 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); A61K 31/444 (2006.01);
U.S. Cl.
CPC ...
C07D 405/06 (2013.01); A61K 31/365 (2013.01); A61K 31/4365 (2013.01); A61K 31/443 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/616 (2013.01); A61K 45/06 (2013.01); C07D 401/06 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01);
Abstract

The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: X is —O—, —N(R), —C(R)(R) or —C(O)—; and Y is —O—, —N(R), —C(R)(R) or —C(O)— and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ACS, secondary prevention of myocardial infarction or stroke, or PAD.


Find Patent Forward Citations

Loading…